Top Biotech Stocks To Research - November 22nd

AbbVie logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Five biotech stocks highlighted for research based on recent dollar trading volume were AbbVie, Amgen, Moderna, Gilead Sciences, and Abivax.
  • The companies span established drug portfolios and development pipelines: AbbVie and Amgen sell treatments across multiple diseases, while Moderna focuses on mRNA vaccines and therapeutics and Gilead on HIV and viral diseases.
  • Abivax is a clinical-stage, higher-risk name, with its lead candidate obefazimod in Phase 3 trials for ulcerative colitis. On Friday, AbbVie shares rose, while the other four stocks declined.
  • MarketBeat previews top five stocks to own in December.

AbbVie, Amgen, Moderna, Gilead Sciences, and Abivax are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies that use biological science to develop products or services, such as medicines, vaccines, diagnostics, and gene therapies. For investors, these stocks can be especially volatile because a company’s value may depend on research results, regulatory approvals, and its ability to fund development. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Shares of NYSE:ABBV traded up $2.65 on Friday, reaching $286.19. 8,754,855 shares of the company traded hands, compared to its average volume of 5,124,685. AbbVie has a 52 week low of $190.75 and a 52 week high of $302.93. The stock has a market capitalization of $505.88 billion, a P/E ratio of 49.26, a price-to-earnings-growth ratio of 1.30 and a beta of 0.20. The business's 50-day simple moving average is $278.98 and its 200 day simple moving average is $242.55.

Read Our Latest Research Report on ABBV

Amgen (AMGN)

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

NASDAQ:AMGN traded down $3.30 during trading hours on Friday, hitting $435.52. The company had a trading volume of 4,942,211 shares, compared to its average volume of 2,619,780. The company has a debt-to-equity ratio of 3.60, a current ratio of 1.48 and a quick ratio of 1.20. The stock has a 50-day moving average price of $430.44 and a 200 day moving average price of $383.81. The company has a market capitalization of $235.58 billion, a PE ratio of 25.26, a price-to-earnings-growth ratio of 3.03 and a beta of 0.43. Amgen has a 52 week low of $312.39 and a 52 week high of $483.99.

Read Our Latest Research Report on AMGN

Moderna (MRNA)

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Shares of NASDAQ:MRNA traded down $5.15 during trading on Friday, hitting $194.18. The stock had a trading volume of 9,660,060 shares, compared to its average volume of 11,300,853. The company has a market capitalization of $78.57 billion, a PE ratio of -27.35 and a beta of 1.16. The company has a quick ratio of 3.47, a current ratio of 3.62 and a debt-to-equity ratio of 0.52. The firm's fifty day moving average is $207.87 and its 200 day moving average is $100.37. Moderna has a 12 month low of $22.28 and a 12 month high of $280.80.

Read Our Latest Research Report on MRNA

Gilead Sciences (GILD)

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

GILD traded down $0.20 during midday trading on Friday, reaching $166.33. The company's stock had a trading volume of 7,554,884 shares, compared to its average volume of 6,363,988. The stock's 50-day moving average is $157.26 and its 200-day moving average is $142.46. The firm has a market capitalization of $206.30 billion, a price-to-earnings ratio of -52.64 and a beta of 0.35. Gilead Sciences has a 1 year low of $116.88 and a 1 year high of $176.58. The company has a current ratio of 1.38, a quick ratio of 1.22 and a debt-to-equity ratio of 1.84.

Read Our Latest Research Report on GILD

Abivax (ABVX)

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.

Shares of ABVX stock traded down $7.13 during mid-day trading on Friday, hitting $73.52. The company's stock had a trading volume of 14,846,382 shares, compared to its average volume of 851,524. Abivax has a 52-week low of $62.70 and a 52-week high of $148.83. The stock has a market cap of $6.44 billion, a price-to-earnings ratio of -12.13 and a beta of 1.36. The business has a 50-day moving average price of $91.16 and a 200 day moving average price of $111.73.

Read Our Latest Research Report on ABVX

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in AbbVie Right Now?

Before you consider AbbVie, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.

While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Related Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines